glp-1 based therapeutics summit Full Event Guide 2nd GLP-1-Based Therapeutics Summit 2025
Description
J., Knop F
From the moment I walked into this office everyone was so nice and welcoming
Eng received a patent for exendin-4 in 1996
doi: 10.1038/s41573-025-01183-8
Rybelsus (oral semaglutide) is included in the litigation as well
